https://www.optimumcomms.com/wp-content/uploads/2023/07/IO-Biotech.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-03 21:30:462023-10-04 08:31:59IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
https://www.optimumcomms.com/wp-content/uploads/2023/02/Amberimplants_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-03 08:14:092023-10-03 08:14:09Amber Implants Announces Start of Clinical Trial with VCFix® Spinal System
https://www.optimumcomms.com/wp-content/uploads/2023/02/FM_Logo_300px.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-02 07:14:002023-10-02 07:14:57European Patent Office grants Futura Medical patent for MED3000 providing protection to 2040
https://www.optimumcomms.com/wp-content/uploads/2023/06/Poolbeg_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-29 09:23:322023-09-29 09:23:32Poolbeg Pharma plc – Positive Conclusion Reached in Immunomodulator I Patent Opposition
https://www.optimumcomms.com/wp-content/uploads/2023/09/WiLD_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-28 12:56:142023-09-28 12:56:48Women in Life Science Denmark (WiLD) launches its Female Leadership Mentoring Program to support career advancement for women in life science
https://www.optimumcomms.com/wp-content/uploads/2023/02/Ariceum_Logo_300x180px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-28 08:56:572023-09-28 08:56:57Ariceum Therapeutics’ targeted radiopharmaceutical 177Lu-satoreotide exhibits promising clinical response and good tolerability profile in patients with advanced neuroendocrine tumours
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-27 08:31:172023-09-27 09:13:484SC receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA
https://www.optimumcomms.com/wp-content/uploads/2023/05/Acension_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-26 07:03:562023-09-26 07:03:56Acesion Pharma Closes Oversubscribed €45M Series B Financing Round
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-25 08:48:482023-09-25 08:48:484SC: Landmark RESMAIN study data presented at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-21 14:00:082023-09-22 11:55:49Novo Holdings advances antimicrobial resistance strategy with acquisition of Paratek Pharmaceuticals
https://www.optimumcomms.com/wp-content/uploads/2023/07/Leucid_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-21 09:03:552023-09-21 09:05:09Leucid Bio Granted MHRA Clinical Trial Authorisation for Lateral NKG2D CAR T-Cell Therapy LEU011
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-21 07:00:052023-09-21 14:24:32New cell therapy facility enters fight against chronic diseases
https://www.optimumcomms.com/wp-content/uploads/2023/06/Poolbeg_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-20 09:02:152023-09-20 09:02:15Poolbeg Pharma plc – Immunomodulator I Patent Portfolio Strengthened
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-19 08:37:502023-09-19 08:37:50Novo Holdings invests in innovative water treatment pioneer, HPNow, as part of €14m round
https://www.optimumcomms.com/wp-content/uploads/2023/02/FM_Logo_300px.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-18 07:30:302023-09-18 07:30:30Futura Medical plc – Interim Results 2023
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-15 08:09:312023-09-15 08:09:314SC: RESMAIN study data to be presented at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-14 08:45:102023-09-14 08:45:10Glentra Capital, a new energy transition investment firm backed by large Danish investors, announces first close of EUR 443 million
https://www.optimumcomms.com/wp-content/uploads/2023/09/hervolution-final-pastel-white.png
1804
3664
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-13 08:44:132023-09-13 08:44:13HERVOLUTION Therapeutics appoints Moderna Co-Founder and MIT Professor Robert S. Langer as Chair of its Scientific Advisory Board
https://www.optimumcomms.com/wp-content/uploads/2023/06/Synaffix_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-13 08:40:262023-09-13 08:40:26ABL Bio Taps into Synaffix ADC Technology
https://www.optimumcomms.com/wp-content/uploads/2023/06/Poolbeg_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-13 07:10:312023-09-13 07:10:31Poolbeg Pharma plc – Interim results for the six months to 30 June 2023For more information about Optimum Strategic Communications, please get in touch.
